Treating volume overload in acutely decompensated heart failure: established and novel therapeutic approaches
Open Access
- 10 July 2012
- journal article
- research article
- Published by Oxford University Press (OUP) in European Heart Journal: Acute Cardiovascular Care
- Vol. 1 (3) , 256-268
Abstract
Most patients hospitalized for acutely decompensated heart failure (ADHF) present with symptoms and signs of volume overload, which is also associated with substantially high rates of death and rehospitalization in ADHF. To review the recent experimental and clinical evidence on existing therapeutic algorithms and investigational drugs used for the treatment of volume overload in ADHF patients. A systematic search of peer-reviewed publications was performed on Medline and EMBASE from January 1990 to March 2012. The results of unpublished trials were obtained from presentations at national and international meetings. Apart from intrinsic renal insufficiency and neurohormonal activation, volume overload through venous congestion may be the primary haemodynamic factor triggering the worsening of renal function in ADHF patients. It is well known that heart and kidneys are closely interrelated and an acute or chronic disorder in one organ may induce acute or chronic dysfunction in the other organ. Established therapeutic strategies, (e.g. loop diuretics, vasodilators, and inotropes), are sometimes associated with limited clinical success due to tolerance and the need for frequent up titration of the doses in order to achieve the desired effect. That leads to an increasing interest in novel options, such as the use of adenosine A1 receptor antagonists, vasopressin antagonists, and renal-protective dopamine. Initial clinical trials have shown quite encouraging results in some heart failure subpopulations but have failed to demonstrate a clear beneficial role of these agents. On the other hand, ultrafiltration appears to be a more promising therapeutic procedure that will improve volume regulation, while preserving renal and cardiac function. Further clinical studies are required in order to determine their net effect on renal function and potential cardiovascular outcomes. Until then, management of volume overload in ADHF patients remains a challenge for the clinicians.Keywords
This publication has 94 references indexed in Scilit:
- Cardiorenal Rescue Study in Acute Decompensated Heart Failure: Rationale and Design of CARRESS-HF, for the Heart Failure Clinical Research NetworkJournal of Cardiac Failure, 2012
- Diuretic Strategies in Patients with Acute Decompensated Heart FailureNew England Journal of Medicine, 2011
- Dyspnoea and Worsening Heart Failure in Patients with Acute Heart Failure: Results from the Pre-RELAX-AHF StudyEuropean Journal of Heart Failure, 2010
- Worsening Renal Function Defined as an Absolute Increase in Serum Creatinine Is a Biased Metric for the Study of Cardio-Renal InteractionsCardiology, 2010
- Potential Effects of Aggressive Decongestion During the Treatment of Decompensated Heart Failure on Renal Function and SurvivalCirculation, 2010
- Importance of Venous Congestion for Worsening of Renal Function in Advanced Decompensated Heart FailureJACC, 2009
- Relaxin, a pleiotropic vasodilator for the treatment of heart failureHeart Failure Reviews, 2008
- Renal effects of ularitide in patients with decompensated heart failureAmerican Heart Journal, 2008
- Characteristics and outcomes of patients hospitalized for heart failure in the United States: Rationale, design, and preliminary observations from the first 100,000 cases in the Acute Decompensated Heart Failure National Registry (ADHERE)American Heart Journal, 2005
- The Effect of Spironolactone on Morbidity and Mortality in Patients with Severe Heart FailureNew England Journal of Medicine, 1999